

RESEARCH MONOGRAPH . COMPOUND PROFILE

Simufilam

A spirocyclic triazaspirodecanone developed by Cassava Sciences to target an altered conformation of the scaffolding protein filamin A in Alzheimer's disease, discontinued in November 2024 after two large Phase 3 randomized controlled trials failed to demonstrate cognitive or functional benefit over placebo.

DOCUMENT	KDC-MN-1659
ISSUED	2026-05-22
REVISION	1.0
AUTHOR	Kodi ac bio l abs Research
COMPOUND CLASS	Small-molecule filamin A conformation modulator proposed to disrupt amyloid beta-driven tau hyperphosphorylation and neuroinflammation in Alzheimer's disease

ABSTRACT

Simufilam (PTI-125) is an oral small-molecule drug candidate of the triazaspirodecanone structural class, developed by Cassava Sciences, Inc. for the treatment of mild-to-moderate Alzheimer's disease (AD). The compound's proposed mechanism centers on binding an altered conformation of the intracellular scaffolding protein filamin A (FLNA) that is reportedly induced by amyloid beta 1-42 (Abeta42) in AD brain tissue. According to the published preclinical literature, simufilam binds altered FLNA with femtomolar affinity and restores its native conformation, thereby disrupting two pathogenic signaling cascades: Abeta42 signaling via the alpha-7 nicotinic acetylcholine receptor (alpha7nAChR) that hyperphosphorylates tau protein, and persistent activation of toll-like receptor 4 (TLR4) that drives neuroinflammation. The proposed mechanism, if validated, would represent a first-in-class approach targeting a protein conformational change rather than a conventional receptor or enzyme.

The preclinical and early clinical pharmacology of simufilam was developed almost entirely within the laboratory of Hoau-Yan Wang at the City University of New York (CUNY), in collaboration with Lindsay Burns, then chief science officer of Cassava Sciences. Published reports from this laboratory described femtomolar binding affinity for altered FLNA, picomolar efficacy in postmortem human brain tissue, and reduction of tau hyperphosphorylation, amyloid aggregation, and inflammatory cytokine release in intracerebroventricular Abeta42-infusion and triple-transgenic mouse models. A Phase 2a open-label study in 13 AD patients (100 mg twice daily for 28 days) reported significant

reductions in cerebrospinal fluid biomarkers of neurodegeneration and neuroinflammation. These results, published in the Journal of Prevention of Alzheimer's Disease in 2020, provided the basis for Phase 3 advancement. However, the Wang laboratory subsequently became the subject of data integrity investigations: a CUNY panel initially cited Wang for "egregious misconduct" across 20 papers (later reversed under a different evidentiary standard), a federal grand jury indicted Wang for fraud involving approximately 16 million dollars in NIH grants (charges later dropped), seven Wang papers have been retracted, and the Journal of Neuroscience issued expressions of concern for two foundational simufilam papers. In September 2024, the U.S. Securities and Exchange Commission charged Cassava Sciences with securities fraud, resulting in a 40 million dollar settlement and the resignation and barring of the chief executive officer and chief science officer. Independent replication of the proposed FLNA conformation-modulation mechanism has not been published by laboratories outside the Wang group.

Two large Phase 3 randomized, double-blind, placebo-controlled trials evaluated simufilam in mild-to-moderate AD. The ReThink-ALZ trial (n = 804, simufilam 100 mg twice daily versus placebo for 52 weeks) found no significant difference on either co-primary endpoint: ADAS-Cog12 (least-squares mean difference negative 0.39, p = 0.431) or ADCS-ADL (difference 0.51, p = 0.403). The ReFocus-ALZ trial (n = 1,125, simufilam 50 mg or 100 mg twice daily versus placebo for 76 weeks) similarly failed all co-primary, secondary, and exploratory biomarker endpoints. No significant changes in plasma p-tau217, neurofilament light chain, or glial fibrillary acidic protein were observed. Simufilam was well tolerated in both trials, with an adverse event profile similar to placebo. Cassava Sciences discontinued the AD program in

November 2024. An independent cell-culture assessment published in 2026 found that simufilam produced no beneficial effects on amyloid processing, neurotrophic factors, or mitochondrial function in differentiated human neuronal cells, aligning with the clinical outcomes.

This monograph documents the chemistry, proposed molecular pharmacology, pharmacokinetics, preclinical pharmacology, the complete clinical evidence base including Phase 3 trial results, the data integrity controversies that accompanied development, sourcing and handling considerations, adverse event profile, and a comparative assessment of five Alzheimer's disease therapeutic candidates against simufilam. The compound is not approved by any regulatory authority for any indication. Investigators considering simufilam for research applications should weigh the absence of independent mechanism validation, the complete Phase 3 clinical failure, and the unresolved questions regarding the integrity of the foundational preclinical data.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Simuflam (assigned circa 2020; the compound was known as PTI-125 through its early preclinical and clinical development phases).

Development code: PTI-125 (Pain Therapeutics, Inc., the corporate predecessor of Cassava Sciences, Inc.). The PTI-125 designation is the canonical identifier in all preclinical pharmacology publications from the Wang laboratory and in the Phase 1 and Phase 2a clinical trial registrations [1, 2, 3].

Other names: Sumifilam (listed as an alternate name on ALZFORUM) [20].

Chemical Abstracts Service registry number: Not assigned or publicly disclosed as of the date of this monograph. The compound is indexed in PubChem under CID 46195331 (free base) and CID 155603443 (dihydrochloride salt) [10].

DrugBank identifier: DB18817 [11].

International Union of Pure and Applied Chemistry name: 4-benzyl-8-methyl-1,4,8-triazaspiro[4.5]decan-3-one [10].

1.2 Structural class and chemistry

Simuflam is a synthetic small molecule belonging to the triazaspirodecanone class. The core scaffold is a 1,4,8-triazaspiro[4.5]decane ring system in which a piperidine ring (containing the 8-methyl nitrogen) is fused through a spiro junction to a five-membered lactam ring (the 3-one), with a benzyl group attached to the nitrogen at position 4 [10]. The spirocyclic architecture confers a rigid three-dimensional geometry that distinguishes the compound from flat aromatic drug scaffolds and is consistent with the proposed high-affinity, conformation-selective binding to the intracellular scaffolding protein filamin A.

Molecular formula: C₁₅H₂₁N₃O (free base); C₁₅H₂₅Cl₂N₃O₂ (dihydrochloride salt) [10].

Molecular weight: 259.35 g/mol (free base) [10].

Exact mass: 259.168 g/mol (monoisotopic, free base) [10].

Canonical SMILES: CN1CCC2(CC1)NCC(=O)N2CC3=CC=CC=C3 [10].

InChI Key: BSQPTZYKCAULBH-UHFFFAOYSA-N [10].

Computed physicochemical properties: XLogP 1.1, hydrogen bond donors 1, hydrogen bond acceptors 3, rotatable bonds 2 [10]. The low lipophilicity, small molecular weight (well within Lipinski rule-of-five parameters), and moderate polar surface area are consistent with oral bioavailability and central nervous system penetration, both of which have been reported in preclinical studies.

Stereochemistry: The compound as represented by the canonical SMILES contains no defined stereocenters. The spiro carbon (position 5 of the triazaspirodecanone numbering) is a quaternary carbon bonded to four distinct substituent chains, but the PubChem record does not specify stereochemical assignment, and no enantiomeric or diastereomeric forms have been distinguished in the published literature [10].

Physical properties: No peer-reviewed characterization of melting point, solubility profile, or crystalline form has been published. The compound is supplied as the dihydrochloride salt for clinical and research use, consistent with enhanced aqueous solubility. Formulated as oral tablets at 50 mg and 100 mg strengths for clinical trials [17, 18].

1.3 Synthesis

No peer-reviewed publication of the synthetic route for simufilam has appeared. The spirocyclic triazaspirodecanone scaffold is accessible through standard heterocyclic chemistry, plausibly involving cyclization of appropriately functionalized piperidine and glycineamide precursors followed by N-benylation. The dihydrochloride salt is prepared by treatment of the free base with hydrogen chloride in a suitable solvent. Cassava Sciences has not disclosed the manufacturing process, and no process-chemistry or scale-up publications are publicly available. Investigators seeking to independently synthesize the compound would need to consult the patent literature (not identified in the present search) or the PubChem structural record as a starting point for retrosynthetic analysis [10].

3. Discovery and Development History

3.1 Origin and early development

Simuflam (originally PTI-125) was developed by Cassava Sciences, Inc. (Austin, Texas; formerly Pain Therapeutics, Inc.), based on research conducted primarily in the laboratory of Hoau-Yan Wang at the City University of New York (CUNY) School of Medicine, in collaboration with Lindsay Burns, who served as the company's senior vice president and later chief science officer [1, 20].

The foundational paper, published by Wang et al. in the *Journal of Neuroscience* in July 2012, described PTI-125 as a novel compound that binds the scaffolding protein filamin A (FLNA) with 200 femtomolar affinity and prevents the toxic signaling of amyloid beta 1-42 (Abeta42) through the alpha-7 nicotinic acetylcholine receptor (alpha7nAChR) [1]. The paper reported that PTI-125 reduced tau hyperphosphorylation, amyloid aggregation, inflammatory cytokine release, and receptor dysfunction in an intracerebroventricular Abeta42-infusion mouse model and in post-mortem human AD brain tissue [1]. This 2012 paper subsequently became the subject of a *Journal of Neuroscience* expression of concern in December 2021, citing concerns about Western blot images [29].

A 2017 paper in *Neurobiology of Aging* extended the preclinical characterization to the triple-transgenic (3xTg) AD mouse model, reporting that two-month oral administration of PTI-125 reduced tau hyperphosphorylation, amyloid deposits, neurofibrillary tangles, and neuroinflammation, with efficacy in postmortem human hippocampal slices at concentrations as low as 1 picomolar [2]. A companion review article in *Neuroimmunology and Neuroinflammation* characterized the altered FLNA conformation as a "third proteopathy" of AD, linking it mechanistically to both the amyloid and tau pathologies [3].

3.2 Clinical development

Clinical development proceeded rapidly following the preclinical publications:

Phase 1 (2017): A first-in-human, double-blind, single ascending dose study (NCT03784300) enrolled 24 healthy adults at doses of 50, 100, and 200 mg. The compound demonstrated dose-proportional pharmacokinetics with a half-life of 4.5 to 6 hours and no drug-related adverse events [12, 20].

Phase 2a (2019): An NIH-funded, open-label, multicenter study (NCT03748706) enrolled 13 patients with mild-to-moderate AD (Mini-Mental State Examination scores 16 to 24, cerebrospinal fluid tau/Abeta42 ratio greater than or equal to 0.30). Participants received 100 mg twice daily for 28 days. Results, published by Wang et al. in the Journal of Prevention of Alzheimer's Disease in 2020, reported significant decreases in cerebrospinal fluid total tau, phosphorylated tau at threonine 181, neurofilament light chain, neurogranin, YKL-40, interleukin-6, interleukin-1 beta, and tumor necrosis factor alpha [6, 13, 20].

Phase 2b (2019 to 2020): A randomized, placebo-controlled study (NCT04079803) enrolled 64 patients at 50 or 100 mg twice daily versus placebo for 28 days. Initial top-line results in May 2020 reported failure to meet the primary endpoint. A subsequent reanalysis in November 2020 claimed 10 to 40 percent biomarker improvements and modest cognitive effect sizes of 17 to 46 percent [14, 20]. In July 2024, a Cassava Sciences internal inquiry disclosed possible unblinding and data inaccuracies in this study [20, 24].

Open-label extension (2020 to 2022): An extension study enrolled up to 200 patients. Six-month interim data reported a 1.6-point improvement on ADAS-Cog in 50 patients; 12-month data in 200 patients showed only a 0.5-point decline, inconsistent with the earlier trajectory claims. A six-month randomized withdrawal study in 2023 failed to meet its primary endpoint, showing no significant difference between continued treatment and placebo [20].

Phase 3 (2021 to 2025): Two large Phase 3 trials were initiated in November 2021 under FDA Special Protocol Assessments. The ReThink-ALZ study (NCT04994483) randomized 804 participants to simufilam 100 mg twice daily versus placebo for 52 weeks. The ReFocus-ALZ study (NCT05026177) randomized 1,125 participants to simufilam 50 mg or 100 mg twice daily versus placebo for 76 weeks [17, 18]. Both trials failed all co-primary, secondary, and exploratory biomarker endpoints [7]. Results are detailed in Section 7.

In October 2022, the FDA rejected an unsolicited breakthrough therapy designation request for simufilam, noting that only sponsors may apply for such designation [20].

3.3 Data integrity controversy

The development of simuflam was accompanied by escalating concerns regarding the integrity of the foundational preclinical data:

In August 2021, the law firm Labaton Sucharow filed a citizen petition with the FDA on behalf of two anonymous whistleblowers, expressing "grave concerns about the quality and integrity of the laboratory-based studies" and alleging manipulation of Western blot images in published papers and conference posters supporting simuflam [28, 29]. Cassava Sciences denied wrongdoing but acknowledged poster figure errors [20, 44].

In February 2022, the FDA rejected the citizen petition on procedural grounds, stating that a citizen petition was "not a proper avenue" to halt clinical trials, but indicated it might eventually take action [30]. In December 2021, the Journal of Neuroscience issued expressions of concern for the foundational 2012 and a 2009 paper by Wang, citing concerns about Western blot images [29]. PLoS One retracted five Wang papers (non-AD-related, though two were co-authored with Burns) in March 2022 [20].

In October 2023, a CUNY investigative panel reported findings of "long-standing and egregious misconduct in data management and record keeping" across 20 of Wang's papers, including foundational simuflam work [21]. However, in May 2024, a CUNY official reversed the misconduct finding in a letter to the Office of Research Integrity, citing a "heightened evidentiary standard" [27]. On June 28, 2024, a federal grand jury indicted Wang on charges of major fraud against the United States, alleging falsified data in clinical samples and grant applications resulting in approximately 16 million dollars of NIH funding [22, 28]. In October 2025, the Department of Justice unexpectedly dropped the criminal charges [26].

In July 2024, Cassava Sciences disclosed results of an internal inquiry that found "possible unblinding and Phase 2b data inaccuracies" [20, 24]. On July 17, 2024, CEO Remi Barbier and CSO Lindsay Burns resigned [20]. On September 26, 2024, the U.S. Securities and Exchange Commission charged Cassava Sciences with securities fraud; the company settled for 40 million dollars, and Barbier and Burns received individual fines and were barred from serving as officers or directors for three to five years [25, 32].

Seven papers by Wang have been retracted as of the date of this monograph [20, 33]. Independent replication of the proposed FLNA conformation-modulation mechanism by laboratories outside the Wang group has not been published.

3.4 Discontinuation and current status

On November 25, 2024, following the ReThink-ALZ failure, Cassava Sciences announced discontinuation of the ReFocus-ALZ study, the open-label extension study (NCT05575076), and the AD program [31]. The company has indicated continued preclinical exploration of simufilam for epilepsy associated with tuberous sclerosis complex, based on the role of filamin A in seizure pathophysiology [20]. No clinical development for any indication is active.

4. Molecular Pharmacology

Investigator note: The molecular pharmacology described in this section is derived almost entirely from publications by the Wang laboratory at CUNY, several of which have received expressions of concern or have been retracted. The proposed mechanism has not been independently replicated. Investigators should interpret the reported binding affinities, functional assays, and downstream pathway claims with awareness of the data integrity concerns documented in Section 3.3 and the complete clinical failure documented in Section 7.

4.1 Filamin A as a proposed therapeutic target

Filamin A (FLNA) is a large (280 kDa) intracellular scaffolding protein composed of 24 immunoglobulin-like repeat domains that dimerizes at its C-terminal near the cell membrane and crosslinks actin filaments at its N-terminal [3, 4]. FLNA interacts with more than 90 protein partners, including multiple transmembrane receptors, and serves as a scaffold for cytoplasmic signaling molecules [3]. Wang and colleagues proposed that Aβ₄₂ induces a conformational change in FLNA, detectable as a shift in isoelectric focusing point from 5.9 (native) to 5.3 (altered) in postmortem human AD brain, and that this altered conformation is resistant to dephosphorylation by alkaline phosphatase, indicating a structural rather than phosphorylation-dependent change [3]. However, Fluegge and Fluegge (2025) have noted that "these experiments prove that FLNA has been altered, but whether this entails a conformational change is not certain," suggesting that proteolytic cleavage rather than conformational rearrangement could account for the observed isoelectric point shift [9].

4.2 Proposed binding to altered FLNA

Wang et al. (2012) reported that PTI-125 binds FLNA with 200 femtomolar affinity [1]. The 2021 review characterized this as femtomolar affinity for the altered (AD) conformation and picomolar affinity for the native (control) conformation, representing approximately 100-fold selectivity for the disease-associated form [3]. In postmortem human brain tissue, the compound reportedly demonstrated efficacy at concentrations as low as 1 picomolar [2, 3]. The binding site was mapped to a

pentapeptide sequence (VAKGL) on FLNA, and a synthetic decoy of this peptide replicated the compound's effects on FLNA-receptor associations, providing evidence that the observed effects were mediated through the proposed FLNA binding site [1].

4.3 Alpha-7 nicotinic acetylcholine receptor pathway

The proposed primary pathogenic cascade involves Abeta42 binding to the alpha7nAChR, which recruits FLNA. Upon recruitment, FLNA undergoes the proposed conformational change, which in turn stabilizes an "ultra-high affinity" Abeta42-alpha7nAChR complex (described as a high-femtomolar, "nearly irreversible, sub-picomolar interaction") [3]. The sequential model proposed by Wang et al. is: (1) Abeta42 binds alpha7nAChR to induce FLNA recruitment; (2) recruitment alters FLNA conformation; (3) altered FLNA locks in the ultra-high-affinity Abeta42-alpha7nAChR interaction [3].

PTI-125 reportedly disrupts this cascade by binding altered FLNA and restoring its native conformation, reducing FLNA-alpha7nAChR association and decreasing Abeta42 affinity for alpha7nAChR by 1,000- to 10,000-fold (from 100 femtomolar to 16 nanomolar in postmortem control tissue; from 770 femtomolar to 1 nanomolar in SK-N-MC neuroblastoma cells) [1]. Using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay, Wang et al. (2023) reported that simufilam reduced Abeta42 binding to alpha7nAChR with an IC50 of 12.6 picomolar (pIC50 = 10.9, plus or minus 0.5) [4].

The downstream consequence of disrupted Abeta42-alpha7nAChR signaling is reported as reduction of tau hyperphosphorylation at three proline-directed sites: serine 202, threonine 231, and threonine 181 [1]. PTI-125 treatment significantly reduced phosphorylation at all three sites ($p < 0.01$) in the intracerebroventricular Abeta42-infusion mouse model [1].

4.4 Toll-like receptor 4 and neuroinflammation pathway

The proposed second pathogenic cascade involves Abeta42 binding to the CD14 co-receptor complexed with toll-like receptor 4 (TLR4), inducing an aberrant FLNA linkage to TLR4 [3]. This linkage reportedly enables persistent TLR4 activation by Abeta42 and excessive release of inflammatory cytokines. PTI-125 disruption of the FLNA-TLR4 interaction was reported to abolish Abeta42-induced interleukin-6 pro-

duction and suppress tumor necrosis factor alpha by 86 percent and interleukin-1 beta by 80 percent in the mouse model [1]. In human astrocyte cultures, simuflam at concentrations of 100 femtomolar to 1 nanomolar reduced release of TNF-alpha, IL-6, and IL-1 beta by approximately 75 percent or more ($p < 0.001$) [4].

4.5 Additional receptor interactions

Wang et al. (2023) extended the characterization of altered FLNA interactions beyond TLR4 to include TLR2, C-X-C chemokine receptor type 4 (CXCR4), C-C chemokine receptor type 5 (CCR5), and T-cell co-receptor cluster of differentiation 4 (CD4), all of which showed elevated FLNA linkages in postmortem human AD brain and in 3xTg-AD transgenic mice [4]. Oral simuflam treatment (22 mg/kg/day for two months) reduced FLNA linkages with these receptors and restored CCR5 responsiveness to its natural ligand CCL3 in transgenic mice [4].

4.6 mTOR and insulin receptor signaling

A separate line of investigation characterized simuflam's effects on mammalian target of rapamycin (mTOR) signaling and insulin sensitivity. Wang et al. (2023) reported that mTOR was overactive and its response to insulin was blunted in lymphocytes from AD patients compared to healthy controls [5]. After 28 days of oral simuflam (100 mg twice daily), lymphocytes from the Phase 2a trial participants showed normalized basal mTOR activity and improved insulin-evoked mTOR activation across mTOR complex 1, complex 2, and upstream (Akt) and downstream (p70S6K, phosphorylated Rictor) signaling components [5]. The proposed mechanism involves FLNA's interaction with the insulin receptor beta subunit, which was elevated in AD lymphocytes and whose insulin-mediated dissociation was impaired; simuflam improved this dissociation [5].

4.7 Independent assessment

Srivastava et al. (2026), in an independent assessment from New York University, investigated simuflam's effects on amyloid processing, neuronal health, and mitochondrial function in differentiated SH-SY5Y human neuronal cells [8]. At concentrations of 5 and 50 micromolar, simuflam did not affect the expression of genes involved in amyloid processing (APP, BACE1, ADAM10). At 50 micromolar in differentiated cells, amyloidogenic beta-secretase (BACE1) protein was significantly increased (fold change 1.17), and brain-derived neurotrophic factor (BDNF) protein

levels were significantly reduced (fold change 0.7) [8]. No improvements in mitochondrial biogenesis genes (TFAM, NRF1, PGC1-alpha), mitochondrial area, or synaptophysin were observed at either concentration [8]. The authors concluded that "insufficient activity across multiple tests of ability to impact processes related to neuronal health can serve as a preliminary indicator of limited clinical utility," aligning with the subsequent Phase 3 clinical failure [8].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Simufilam is rapidly absorbed after oral administration. In the Phase 1 single ascending dose study (NCT03784300) in 24 healthy adults, pharmacokinetics were dose-proportional across 50, 100, and 200 mg doses [12, 20]. In the Phase 2a study (NCT03748706), 13 AD patients receiving 100 mg tablets showed a Day 1 peak plasma concentration (C_{max}) of 1,020 plus or minus 442 ng/mL (approximately 3.9 micromolar based on the free base molecular weight of 259.35 g/mol) with a median time to peak (T_{max}) of 2.0 hours (range 1.0 to 3.0 hours) [6, 20]. On Day 28 of repeated dosing, C_{max} was 1,100 plus or minus 417 ng/mL with a median T_{max} of 2.06 hours (range 1.0 to 5.93 hours), indicating minimal change in absorption parameters with chronic administration [6, 20].

Preclinical studies in rats and dogs reported nearly 100 percent oral bioavailability with dose-proportional pharmacokinetics and no accumulation [20]. Human oral bioavailability has not been formally characterized in a published crossover study.

A food effect and bioequivalence study (NCT04932655) was completed in 24 healthy volunteers in May 2021 [16]. Results have not been published in peer-reviewed form.

5.2 Distribution

No published data are available on plasma protein binding, volume of distribution, or cerebrospinal fluid penetration in humans. The compound's physicochemical properties (molecular weight 259.35 g/mol, XLogP 1.1, one hydrogen bond donor, three acceptors) are consistent with blood-brain barrier penetration [10]. The proposed intracellular target (FLNA) requires cellular uptake, and the preclinical efficacy in central nervous system tissue (postmortem human brain slices, transgenic

mouse brain) implies adequate brain distribution, though formal quantification by positron emission tomography or cerebrospinal fluid sampling has not been published.

5.3 Metabolism and elimination

In vitro metabolic profiling across several species, including humans, indicated minimal metabolism [20]. No specific cytochrome P450 enzyme involvement has been published, and no major metabolites have been characterized in the public literature. The plasma elimination half-life in healthy volunteers was 4.5 to 6 hours in the Phase 1 study [12, 20]. In the repeated-dose Phase 2a study, the accumulation ratio was 1.36, and steady-state concentrations were achieved by Day 7, consistent with the measured half-life and twice-daily dosing [6, 20].

The route of elimination (renal versus hepatic) has not been characterized in published studies. No data on pharmacokinetics in hepatic or renal impairment, in elderly versus young populations, or across sex or ethnic subgroups have been formally published.

5.4 Routes of administration and formulation

Simufilam was administered exclusively by the oral route in all clinical studies. Formulations included oral tablets at 50 mg and 100 mg strengths [17, 18]. The clinical dosing regimen in Phase 2 and Phase 3 trials was 50 mg or 100 mg twice daily (morning and evening), with or without food. No parenteral, subcutaneous, or intramuscular formulations have been described.

5.5 Pharmacokinetic limitations

The published pharmacokinetic characterization of simufilam is notably incomplete for a compound that advanced to Phase 3. Formal data on bioavailability, protein binding, volume of distribution, metabolic pathways, renal and hepatic clearance, and drug-drug interaction potential have not appeared in peer-reviewed publications. This gap limits the ability of independent investigators to model dose-response relationships, predict interactions, or design pharmacokinetic-informed research protocols.

6. Preclinical Pharmacology

6.1 In vivo models

Intracerebroventricular Abeta42-infusion model (Wang et al. 2012): Eight-week-old male and female E129 mice (30 to 35 g) received intracerebroventricular infusion of Abeta42 (4.8 nmol daily for 7 days via Alzet osmotic minipump at 0.2 nmol/microliter at 0.1 microliter/hour) [1]. PTI-125 was administered at 10 mg/kg by intraperitoneal injection twice daily for 14 days. Synaptosomes prepared from prefrontal cortex and hippocampus showed significant reductions in FLNA- α 7nAChR and FLNA-TLR4 associations ($p < 0.01$), tau phosphorylation at serine 202, threonine 231, and threonine 181 ($p < 0.01$), Abeta42- α 7nAChR complex levels (60 percent reduction in hippocampus, 75 percent in prefrontal cortex), and inflammatory cytokines (IL-6 abolished, TNF- α reduced 86 percent, IL-1 beta reduced 80 percent) [1]. Agonist-evoked calcium influx through α 7nAChR and NMDA receptors was normalized [1]. This study used co-immunoprecipitation and Western blotting as primary quantification methods, both of which are the techniques under data integrity scrutiny [1, 29].

Triple-transgenic (3xTg) AD mouse model (Wang et al. 2017): Mice expressing APP Swedish, MAPT P301L, and PSEN1 M146V mutations received two-month oral PTI-125 administration both before and after the onset of apparent neuropathology [2]. Eight-month-old wildtype mice with milder neuropathologies were also treated. PTI-125 reduced receptor dysfunctions, improved synaptic plasticity (evidenced by improved activity-dependent expression of Arc protein), reduced tau hyperphosphorylation, aggregated Abeta42 deposition, neurofibrillary tangles, and neuroinflammation, with some improvements in nesting behavior and spatial and working memory in 3xTg AD mice [2]. Efficacy in postmortem human AD and Abeta42-treated age-matched control hippocampal slices was concentration-dependent starting at 1 picomolar [2].

3xTg-AD mice, extended receptor panel (Wang et al. 2023): Six- and ten-month-old 3xTg-AD transgenic mice versus age-matched wildtypes were treated with oral simufilam at 22 mg/kg/day in drinking water for two months [4]. Simufilam reduced aberrant FLNA linkages with TLR2, CXCR4, CCR5, and CD4, and restored CCR5 responsiveness to CCL3 stimulation (restoration of G-protein coupling dynamics) [4].

6.2 In vitro systems

Human neuroblastoma cells (SK-N-MC): PTI-125 at 1 nanomolar reduced Abeta42 affinity for alpha7nAChR by 10,000-fold (from 770 femtomolar to 1 nanomolar) [1].

Postmortem human brain tissue: PTI-125 was effective in postmortem human frontal cortex slices (200 micrometer thickness) from the Harvard Brain Tissue Resource Center and University of Pittsburgh Brain Tissue Resource Center (post-mortem interval less than 10 hours to 13 hours), reducing FLNA-receptor associations and tau hyperphosphorylation [1, 2, 3]. In immunopurified FLNA from post-mortem tissue, the compound demonstrated 100-fold higher binding affinity for AD-derived FLNA versus control-derived FLNA [3].

Human astrocytes: Simufilam at 100 femtomolar, 10 picomolar, or 1 nanomolar reduced inflammatory cytokine release by approximately 75 percent or more ($p < 0.001$) [4].

AD patient lymphocytes: In the Phase 2a cohort (13 patients, 100 mg twice daily for 28 days), lymphocytes collected at baseline, Day 14, and Day 28 showed normalized basal mTOR activity, improved insulin-evoked mTOR activation, improved FLNA-insulin receptor dissociation, and increased FLNA-PTEN interaction [5].

6.3 Assay methodology and data integrity considerations

The primary assay methods across the Wang laboratory publications were co-immunoprecipitation (for detecting protein-protein interactions such as FLNA-alpha7nAChR and FLNA-TLR4 associations), Western blotting with densitometric scanning (for quantification), calcium-45 influx assays (for receptor function), immunohistochemistry (for amyloid and neurofibrillary pathology), fluorescence ELISA (for cytokines), and TR-FRET (for Abeta42-alpha7nAChR binding) [1, 2, 4].

Co-immunoprecipitation and Western blotting are the techniques for which data integrity concerns have been raised. The August 2021 citizen petition alleged manipulation of Western blot images in published studies and conference posters [29]. The CUNY investigative panel, before reversal of its finding, cited "long-standing and egregious misconduct in data management and record keeping" and noted that Wang had discarded lab notebooks and raw data [21]. Seven papers by Wang have been retracted, and expressions of concern have been issued for two foundational simufilam papers in the Journal of Neuroscience [20, 29, 33]. Investigators should

interpret the quantitative claims from these publications with awareness that independent replication of the FLNA-based mechanism by other laboratories has not been published.

6.4 Independent cell-culture assessment

The only published independent assessment of simuflam's cellular effects comes from Srivastava et al. (2026) at NYU [8]. Using differentiated SH-SY5Y human neuronal cells, the study found no effect on amyloid processing gene expression, a paradoxical increase in BACE1 protein at 50 micromolar, a decrease in BDNF protein at 50 micromolar, and no improvement in mitochondrial genes, mitochondrial area, or synaptophysin at either 5 or 50 micromolar [8]. The authors concluded that these results "align with clinical outcomes and indicate that insufficient activity across multiple tests of ability to impact processes related to neuronal health can serve as a preliminary indicator of limited clinical utility" [8].

7. Clinical Evidence Base

Regulatory note: Simuflam is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any other regulatory authority for any indication. The compound advanced to Phase 3 clinical trials but failed to demonstrate efficacy. The following clinical evidence is presented for research reference only.

7.1 Phase 1

A first-in-human, double-blind, single ascending dose, placebo-controlled study (NCT03784300) enrolled 24 healthy adults aged 18 to 45 in 2017 [12, 20]. Doses of 50, 100, and 200 mg were tested. Pharmacokinetics were dose-proportional with a plasma half-life of 4.5 to 6 hours. No drug-related adverse events were reported [12, 20].

7.2 Phase 2a

An NIH-funded, open-label, multicenter Phase 2a study (NCT03748706) enrolled 13 patients with mild-to-moderate AD (MMSE 16 to 24, CSF tau/Abeta42 ratio greater than or equal to 0.30) [13, 6, 20]. Participants received 100 mg twice daily for 28 days. The study was designed with pharmacokinetics as the primary outcome and cerebrospinal fluid biomarkers as secondary outcomes.

Wang et al. (2020) reported significant decreases in CSF total tau, phosphorylated tau at threonine 181, neurofilament light chain, neurogranin, YKL-40, interleukin-6, interleukin-1 beta, and tumor necrosis factor alpha [6]. These biomarker findings, from a 13-patient open-label study without a placebo comparator, provided the principal clinical rationale for Phase 3 advancement. The study was conducted by the Wang laboratory team, and the biomarker analyses were performed using the same assay methods (including Western blotting) that subsequently came under data integrity scrutiny [6, 20, 24].

7.3 Phase 2b

A randomized, placebo-controlled Phase 2b study (NCT04079803) enrolled 64 patients at 10 U.S. sites, randomized to 50 mg twice daily, 100 mg twice daily, or placebo for 28 days [14, 20]. Initial top-line results (May 2020) reported failure to meet the primary endpoint (CSF biomarker changes) [20]. A reanalysis published in November 2020 claimed improvements of 10 to 40 percent across biomarkers and modest cognitive effect sizes of 17 to 46 percent [20].

In July 2024, Cassava Sciences disclosed the results of an internal inquiry that identified "possible unblinding and Phase 2b data inaccuracies" in this study [20, 24]. The specific nature and extent of the data inaccuracies have not been fully detailed publicly.

7.4 Open-label extension

An open-label extension enrolled up to 200 patients receiving simuflam 100 mg twice daily through December 2022 [20]. Reported outcomes were inconsistent: six-month interim data (February 2021) reported 1.6-point improvement on ADAS-Cog and 1.3 on the Neuropsychiatric Inventory in 50 patients; nine-month data (July 2021) reported 3-point ADAS-Cog improvement in the first 50 patients; but 12-month data (January 2023) in 200 patients showed only a 0.5-point decline on ADAS-Cog [20]. The expected decline for untreated mild-to-moderate AD patients over 12 months is approximately 4 to 7 points on ADAS-Cog, making the open-label data difficult to interpret without a concurrent placebo arm. A six-month randomized withdrawal sub-study conducted in 2023 failed to meet its primary endpoint, finding no significant difference between continued simuflam treatment and placebo withdrawal [20].

7.5 Phase 3: ReThink-ALZ

The ReThink-ALZ study (NCT04994483) was a Phase 3, randomized, double-blind, placebo-controlled trial [7, 17]. A total of 2,271 participants were screened and 804 were randomized (403 simuflam, 401 placebo). Participants were aged 50 to 87 with mild-to-moderate AD (MMSE 16 to 27, Clinical Dementia Rating Global Score 0.5, 1, or 2), with AD pathology supported by plasma phosphorylated tau at threonine 181 (p-tau181) or prior amyloid positron emission tomography [7].

The intervention was simufilam 100 mg tablets taken twice daily for 52 weeks. Co-primary endpoints were change from baseline on the Alzheimer's Disease Assessment Scale, Cognitive Subscale, 12 items (ADAS-Cog12) and the Alzheimer's Disease Cooperative Study, Activities of Daily Living (ADCS-ADL) [7].

Results: Simufilam failed both co-primary endpoints. On ADAS-Cog12, the least-squares mean change from baseline was 2.79 for simufilam and 3.19 for placebo (difference negative 0.39; 95 percent confidence interval negative 1.37 to 0.59; $p = 0.431$). On ADCS-ADL, the least-squares mean change was negative 3.26 for simufilam and negative 3.76 for placebo (difference 0.51; 95 percent confidence interval negative 0.68 to 1.70; $p = 0.403$) [7].

All secondary endpoints were non-significant: integrated Alzheimer's Disease Rating Scale ($p = 0.248$), Neuropsychiatric Inventory ($p = 0.647$), MMSE ($p = 0.522$), Clinical Dementia Rating Sum of Boxes ($p = 0.281$), and Zarit Burden Interview ($p = 0.773$) [7].

Plasma biomarkers showed no significant differences between simufilam and placebo: phosphorylated tau 217 ($p = 0.746$), glial fibrillary acidic protein ($p = 0.172$), neurofilament light chain ($p = 0.225$), and total tau ($p = 0.448$) [7].

Completion rates were 77.7 percent for simufilam and 81.7 percent for placebo, with 162 participants (20.3 percent) discontinuing [7].

7.6 Phase 3: ReFocus-ALZ

The ReFocus-ALZ study (NCT05026177) was a Phase 3, randomized, double-blind, placebo-controlled, three-arm trial [7, 18]. A total of 2,671 participants were screened and 1,125 were randomized (376 simufilam 50 mg, 374 simufilam 100 mg, 375 placebo). Enrollment criteria and endpoints matched ReThink-ALZ, with a 76-week treatment duration [7].

Results: The trial was terminated early on November 25, 2024, following the ReThink-ALZ failure [31]. At termination, 22 percent of participants were still active, and 53 percent had completed Week 76 [7].

Both doses of simufilam failed all co-primary endpoints. On ADAS-Cog12, the difference between simufilam 100 mg and placebo was 0.27 (95 percent confidence interval negative 0.97 to 1.51; $p = 0.666$); between simufilam 50 mg and placebo, 0.56

($p = 0.375$) [7]. On ADCS-ADL, the difference for 100 mg versus placebo was negative 0.95 (95 percent confidence interval negative 2.50 to 0.60; $p = 0.232$) [7].

All secondary endpoints were non-significant across both doses [7]. Plasma biomarkers showed no significant changes [7].

A predefined mild subgroup analysis in ReFocus-ALZ showed simufilam 100 mg was associated with slower cognitive decline on ADAS-Cog12 through Week 64 ($p = 0.019$), but this signal disappeared at Week 76 with 45 percent missing data and did not replicate in ReThink-ALZ [7].

A critical finding from the ReFocus-ALZ amyloid PET sub-study was that 20.6 percent (33 of 160) of baseline amyloid PET scans were amyloid-negative, indicating that the plasma p-tau181 screening criterion had low predictive power for amyloid pathology and that a substantial fraction of enrolled participants may not have had the amyloid-driven disease that simufilam was designed to treat [7].

7.7 Summary of clinical evidence

Across two Phase 3 trials enrolling 1,929 participants with mild-to-moderate AD, simufilam at 50 mg or 100 mg twice daily for up to 76 weeks produced no significant improvement on any cognitive, functional, behavioral, or biomarker endpoint compared to placebo [7]. The clinical program is discontinued.

8. Sourcing and Quality Verification

Simuflam is not commercially available as a registered pharmaceutical product. The compound was manufactured by Cassava Sciences for clinical trial use at 50 mg and 100 mg oral tablet strengths.

Research-grade simuflam may be available from specialty chemical suppliers. As of the date of this monograph, the compound appears in PubChem (CID 46195331) and DrugBank (DB18817) [10, 11]. Investigators seeking research-grade material should consult chemical suppliers specializing in pharmaceutical reference standards and screening compounds, such as MedChemExpress, Selleckchem, Cayman Chemical, or Tocris, for availability. Given that the compound's development has been discontinued and its mechanism is unvalidated, supply may be limited to custom synthesis.

Investigators who acquire research-grade simuflam should verify compound identity and purity through:

- High-performance liquid chromatography with area-percent purity determination (target greater than 95 percent)
- Mass spectrometry confirmation of molecular weight (expected $[M+H]^+ = 260.18$ for the free base)
- Nuclear magnetic resonance spectroscopy (proton and carbon-13) for structural confirmation
- Karl Fischer analysis for residual water content in solid preparations

Given the data integrity concerns surrounding the compound's published pharmacology, independent analytical confirmation is essential for any investigation that intends to evaluate the compound's biological activity. Reliance on supplier certificates of analysis alone is insufficient for studies designed to test mechanism-of-action claims.

9. Reconstitution and Handling

Simufilam is a small organic molecule with favorable physicochemical properties for handling and formulation. The dihydrochloride salt form is expected to be freely soluble in water and in common polar organic solvents (dimethyl sulfoxide, methanol) based on the molecular weight (259.35 g/mol free base), XLogP (1.1), and salt form [10].

For in vitro research applications, stock solutions may be prepared in dimethyl sulfoxide at concentrations of 10 to 100 millimolar, aliquoted, and stored at negative 20 degrees Celsius. Working solutions should be prepared fresh by dilution into aqueous buffer or cell culture medium. The published in vitro concentrations used in the Wang laboratory ranged from 100 femtomolar to 1 nanomolar for mechanistic studies [1, 4] and 5 to 50 micromolar in the independent SH-SY5Y assessment [8].

For animal studies, the compound was administered intraperitoneally at 10 mg/kg twice daily (dissolved in vehicle, specific vehicle not described) [1] or orally in drinking water at 22 mg/kg/day [4]. The oral tablet formulation used in clinical trials was produced at 50 mg and 100 mg strengths; the excipient composition has not been publicly disclosed [17, 18].

Storage conditions for the solid compound should be refrigerated (2 to 8 degrees Celsius) with desiccation and protection from light until formal stability data are available. Aqueous solutions should be used within 24 hours of preparation unless stability has been independently characterized.

10. Stack Interaction Considerations

10.1 Metabolic interactions

Formal drug-drug interaction studies with simuflam have not been published. In vitro metabolic profiling indicated minimal metabolism across species including humans [20]. The absence of published data on cytochrome P450 substrate, inhibitor, or inducer status means that the metabolic interaction potential is unknown. Investigators combining simuflam with cytochrome P450 substrates or inhibitors in research protocols should monitor for unexpected pharmacokinetic changes.

10.2 Pharmacodynamic interactions

The proposed mechanism of simuflam (modulation of FLNA conformation) is distinct from conventional receptor agonism, antagonism, or enzyme inhibition. No published evidence suggests direct pharmacodynamic interactions with standard Alzheimer's disease medications (cholinesterase inhibitors, NMDA receptor antagonists) or with common concomitant therapies (antidepressants, antipsychotics, antihypertensives). In the Phase 3 trials, participants were permitted to continue stable background Alzheimer's therapy, and no interaction signals were reported [7].

10.3 Combinations of research interest

Given the failed Phase 3 program and unvalidated mechanism, combinations of simuflam with other investigational agents are of limited current interest. Hypothetical combinations that might be considered in fundamental research include:

Anti-amyloid agents (lecanemab, donanemab): The proposed FLNA mechanism operates downstream of amyloid formation; combination with upstream amyloid clearance could theoretically be additive if the FLNA mechanism were validated. No preclinical or clinical combination data exist.

Cholinesterase inhibitors (donepezil, rivastigmine): The proposed mechanism involves $\alpha 7$ nAChR signaling, which is modulated by acetylcholine availability. In the Phase 3 trials, concomitant cholinesterase inhibitor use was permitted; no subgroup interaction analyses have been published [7].

Anti-inflammatory agents: Given the proposed TLR4-mediated anti-inflammatory mechanism, combination with other neuroinflammatory modulators (p38 MAPK inhibitors, RAGE antagonists) could produce overlapping effects, but the clinical relevance is moot given the absence of demonstrated efficacy for simufilam.

11. Adverse Events and Safety

11.1 Phase 1 safety

No drug-related adverse events were reported in the 24 healthy volunteers who received single doses of 50, 100, or 200 mg [12, 20].

11.2 Phase 3 safety: ReThink-ALZ

In the ReThink-ALZ trial (n = 804, 52 weeks), the overall adverse event profile was similar between simufilam and placebo [7]:

- Any treatment-emergent adverse event (TEAE): simufilam 71.2 percent, placebo 67.6 percent
- Drug-related TEAE: simufilam 17.0 percent, placebo 12.3 percent
- Serious TEAE: simufilam 13.0 percent, placebo 9.0 percent
- Discontinued due to TEAE: simufilam 6.5 percent, placebo 4.3 percent
- Deaths: simufilam 1 (cardiac arrest, unrelated), placebo 3 (all unrelated) [7]

Notable differences: dizziness occurred in 5.3 percent of the simufilam group versus 0.3 percent of the placebo group, a clinically meaningful imbalance [7]. Hip fracture occurred in 7 simufilam-treated participants (1.8 percent) versus 1 placebo participant (0.3 percent); this difference did not reach statistical significance (p = 0.08) but warrants attention given the vulnerable population [7]. Falls occurred at equal rates (7.5 percent in both groups) [7].

No clinically significant changes in physical examination, neurological examination, laboratory values, vital signs, electrocardiogram parameters, renal function, or suicidality assessments (Columbia Suicide Severity Rating Scale, 0.5 to 1.3 percent) were observed [7].

11.3 Phase 3 safety: ReFocus-ALZ

In the ReFocus-ALZ trial (n = 1,125, up to 76 weeks), adverse event rates were similar across all three arms [7]:

- Any TEAE: simufilam 50 mg 76.6 percent, simufilam 100 mg 76.5 percent, placebo 75.6 percent
- Drug-related TEAE: simufilam 50 mg 13.3 percent, simufilam 100 mg 16.7 percent, placebo 14.2 percent
- Serious TEAE: simufilam 50 mg 16.2 percent, simufilam 100 mg 11.5 percent, placebo 12.1 percent
- Discontinued due to TEAE: simufilam 50 mg 9.0 percent, simufilam 100 mg 8.6 percent, placebo 4.6 percent
- Deaths: simufilam 50 mg 6, simufilam 100 mg 2, placebo 3 (none therapy-related) [7]

The hip fracture imbalance observed in ReThink-ALZ was not replicated in ReFocus-ALZ (50 mg: 0.8 percent, 100 mg: 0.3 percent, placebo: 0.5 percent) [7]. The dizziness signal was consistent but smaller in magnitude.

11.4 Overall safety assessment

Across both Phase 3 trials (1,929 participants, up to 76 weeks of exposure), simufilam demonstrated an overall favorable safety profile [7]. The most notable adverse event signal was dizziness, which was more frequent with simufilam than placebo. The hip fracture imbalance in ReThink-ALZ was not statistically significant and was not replicated in ReFocus-ALZ. No dose-dependent safety signals emerged from the three-arm ReFocus-ALZ design. The Phase 3 trial publication concluded: "Simufilam was safe and well tolerated" [7].

12. Comparable Compounds Assessment

This section compares simuflam against five alternative therapeutic approaches for Alzheimer's disease that have reached late-stage clinical evaluation. The comparator set includes two approved anti-amyloid antibodies (lecanemab, donanemab), one conditionally approved anti-neuroinflammatory oral agent (GV-971/sodium oligomannate), and two discontinued or repositioned oral small molecules targeting neuroinflammatory pathways (azeliragon, neflamapimod). Each comparator is evaluated on five standards: novelty, effect size, promising potential, side-effect profile, and overall validation.

12.1 Lecanemab (Leqembi)

Mechanism: Humanized monoclonal antibody targeting soluble amyloid beta protofibrils, administered by intravenous infusion every two weeks. Lecanemab binds and clears soluble aggregated amyloid species from brain parenchyma, reducing amyloid plaque burden [39].

Development trajectory: Eisai and Biogen advanced lecanemab through Phase 2 (BAN2401-G000-201, Study 201) and the pivotal Phase 3 CLARITY AD trial. The CLARITY AD trial (n = 1,795, early AD with confirmed amyloid pathology, 18 months) reported a statistically significant 27 percent slowing of cognitive decline on CDR-SB (least-squares mean difference negative 0.45 points; 95 percent confidence interval negative 0.67 to negative 0.23; $p < 0.001$) and significant benefits on secondary endpoints including ADAS-Cog14, ADCS-MCI-ADL, and amyloid PET [39]. Lecanemab received full FDA approval in January 2023.

Novelty: 3/5. Anti-amyloid antibody therapy represents a well-explored mechanism, but lecanemab's selectivity for protofibrils over monomers or fibrils is a meaningful pharmacological distinction.

Effect size: 3/5. The 0.45-point CDR-SB benefit over 18 months represents a statistically significant but clinically modest effect. The clinical meaningfulness of this magnitude of slowing continues to be debated.

Promising potential: 5/5. FDA-approved, commercially available, actively prescribed, with confirmatory real-world data accumulating.

Side-effect profile: 2/5. Amyloid-related imaging abnormalities (ARIA) are the principal safety concern: ARIA-edema occurred in approximately 13 percent and ARIA-hemorrhage (microhemorrhages) in approximately 17 percent of lecanemab-treated patients in CLARITY AD [39]. ARIA is more common and more severe in APOE-epsilon4 homozygotes. Infusion reactions and other adverse events are manageable but the ARIA risk requires MRI monitoring.

Overall validation: 5/5. Lecanemab is the most rigorously validated currently approved disease-modifying therapy for AD, with consistent Phase 2 and Phase 3 data, amyloid biomarker confirmation, and regulatory approval.

Comparison to simufilam: Lecanemab demonstrated statistically significant and replicated clinical efficacy; simufilam showed no efficacy on any endpoint. Lecanemab's mechanism (direct amyloid clearance) is independently validated by multiple laboratories; simufilam's mechanism (FLNA conformation modulation) has not been independently replicated. Lecanemab carries meaningful safety risks (ARIA); simufilam was well tolerated. Lecanemab requires biweekly intravenous infusion and MRI monitoring; simufilam was an oral tablet.

12.2 Donanemab (Kisunla)

Mechanism: Humanized monoclonal antibody targeting a pyroglutamate-modified form of amyloid beta (N3pG-Abeta) deposited in plaques, administered by intravenous infusion every four weeks. Donanemab selectively binds deposited amyloid plaques and clears them more rapidly than lecanemab [40].

Development trajectory: Eli Lilly advanced donanemab through the TRAILBLAZER-ALZ 2 Phase 3 trial (n = 1,736, early symptomatic AD with confirmed amyloid and tau pathology, 76 weeks). The trial reported a 35 percent slowing of decline on iADRS in the combined population (p < 0.001) and 36 percent on CDR-SB in the low/medium tau subgroup [40]. FDA approved donanemab in July 2024.

Novelty: 3/5. Shares the anti-amyloid antibody mechanism class with lecanemab but targets a different amyloid epitope and employs a treat-to-clearance dosing model.

Effect size: 4/5. The 35 to 36 percent slowing across cognitive and functional endpoints represents the largest effect size demonstrated in a Phase 3 AD trial to date. In the low/medium tau subgroup, 47 percent of donanemab-treated patients showed no decline on CDR-SB at 12 months [40].

Promising potential: 5/5. FDA-approved, commercially available, with a novel dosing paradigm (treatment may be stopped after amyloid clearance).

Side-effect profile: 2/5. ARIA-edema approximately 24 percent, ARIA-hemorrhage approximately 31 percent (higher than lecanemab). Three ARIA-related deaths occurred in the trial [40]. The ARIA risk is more severe than for lecanemab and requires careful MRI monitoring.

Overall validation: 5/5. The largest Phase 3 effect sizes in AD, with subgroup-stratified analysis, biomarker confirmation, and regulatory approval.

Comparison to simufilam: The contrast is stark: donanemab demonstrated the largest clinical effect sizes in AD Phase 3 trials; simufilam demonstrated no effect on any endpoint. Both were tested in similar populations (mild-to-moderate AD), but donanemab required confirmed amyloid and tau pathology, while simufilam's p-tau181 screening allowed 20.6 percent amyloid-negative participants. Donanemab carries substantial ARIA risk; simufilam was well tolerated.

12.3 GV-971 (Sodium Oligomannate)

Mechanism: Marine-derived oligosaccharide mixture from brown algae, proposed to act through remodeling the gut microbiome to reduce peripheral immune cell infiltration into the brain and suppress neuroinflammation [34, 35]. Administered orally at 450 mg three times daily.

Development trajectory: Shanghai Green Valley Pharmaceuticals conducted a Phase 3 trial (n = 818, mild-to-moderate AD, 36 weeks) in China, reporting a treatment difference of negative 2.15 points on ADAS-Cog12 (95 percent confidence interval negative 3.07 to negative 1.23; $p < 0.0001$; effect size 0.531), with drug-placebo differences emerging at Week 4 [34]. GV-971 received conditional marketing approval in China in November 2019 [35]. A global Phase 3 trial (Green Memory, planned n = 2,046) was initiated in October 2020 but terminated early due to financing problems and complications of the COVID-19 pandemic, with only 439 of the planned participants randomized [35].

Novelty: 4/5. The gut-microbiome-neuroinflammation axis represents a novel therapeutic concept for AD, distinct from conventional amyloid-targeting approaches.

Effect size: 3/5. The 2.15-point ADAS-Cog12 benefit over 36 weeks (effect size 0.531) is moderate, though the single-trial basis and the failure to meet secondary endpoints limit confidence.

Promising potential: 2/5. Approved only in China under conditional terms. The terminated global Phase 3 trial leaves international regulatory prospects uncertain. Post-marketing surveillance continues in China.

Side-effect profile: 4/5. Treatment-emergent adverse events were comparable to placebo (73.9 percent versus 75.4 percent) [34]. No significant safety signals have been reported. The oral route and favorable tolerability are advantages.

Overall validation: 2/5. A single positive Phase 3 trial in one jurisdiction, with secondary endpoints not met, no completed global confirmatory trial, and integrity concerns regarding published supporting research (a Chinese integrity panel issued formal criticism of the lead scientist for "misuse of graphics") [35].

Comparison to simuflam: Both GV-971 and simuflam are oral compounds with novel proposed mechanisms for AD, and both have been accompanied by data integrity questions. GV-971 demonstrated statistical significance on its primary endpoint in a Phase 3 trial; simuflam did not. GV-971 received conditional approval in one jurisdiction; simuflam's development is discontinued. Both compounds lack a completed, positive, global confirmatory trial.

12.4 Azeliragon (TTP488)

Mechanism: Oral small-molecule antagonist of the receptor for advanced glycation endproducts (RAGE), which mediates transport of amyloid beta across the blood-brain barrier and activates neuroinflammatory cascades [36, 37]. Administered orally at 5 mg daily.

Development trajectory: Developed by TransTech Pharma/vTv Therapeutics, azeliragon advanced through a Phase 2 program and the Phase 3 STEADFAST trial (n = 880, mild AD, 5 mg daily, 18 months). STEADFAST failed to meet co-primary

endpoints on ADAS-Cog and CDR-SB [37]. A subsequent Phase 2/3 trial in AD patients with elevated HbA1c (n = 43) also missed the ADAS-Cog endpoint [37]. Development was discontinued by end of 2020.

Novelty: 3/5. The RAGE target represents a novel approach to AD at the blood-brain barrier interface, distinct from direct amyloid clearance or conventional neurotransmitter modulation.

Effect size: 1/5. No significant efficacy demonstrated in Phase 3 or in the follow-up Phase 2/3 study.

Promising potential: 1/5. Development discontinued. No active clinical programs.

Side-effect profile: 3/5. The 5 mg dose was generally well tolerated; a higher dose tested in Phase 2 "flagged both safety signals and faster deterioration" and was discontinued [37].

Overall validation: 2/5. The compound advanced through rigorous Phase 3 development but failed to demonstrate efficacy. The RAGE mechanism remains pharmacologically plausible but unvalidated clinically in AD.

Comparison to simufilam: Both azeliragon and simufilam are oral small molecules targeting non-amyloid mechanisms in AD, and both failed Phase 3 trials. Azeliragon's development was not accompanied by the data integrity concerns that shadowed simufilam. Both compounds demonstrated acceptable tolerability without efficacy.

12.5 Neflamapimod (VX-745)

Mechanism: Selective inhibitor of p38 mitogen-activated protein kinase alpha (p38-alpha MAPK), a stress kinase that activates neuroinflammatory pathways and impairs Rab5-mediated endosomal function relevant to synaptic signaling [38]. Administered orally at 40 mg two to three times daily.

Development trajectory: Developed by EIP Pharma (now CervoMed), neflamapimod was tested in the REVERSE-SD Phase 2 trial (n = 161, mild AD with biomarker confirmation, 40 mg twice daily, 24 weeks). The trial failed to meet its primary endpoint (Hopkins Verbal Learning Test) [38]. Neflamapimod was subsequently tested in dementia with Lewy bodies: the AscenD-LB Phase 2 trial (n = 91, 40 mg three

times daily, 16 weeks) met its primary cognitive endpoint with thrice-daily dosing [38]. The follow-up RewinD-LB Phase 2b trial (n = 160) missed endpoints, attributed to expired capsules failing to achieve target plasma concentrations [38]. Development continues in dementia with Lewy bodies and frontotemporal dementia, with orphan drug designation granted for the latter in November 2024 [38].

Novelty: 4/5. The p38 MAPK alpha mechanism targets a specific kinase involved in neuroinflammation and synaptic dysfunction, representing a more molecularly defined approach than broad anti-inflammatory strategies.

Effect size: 2/5. No significant effect in the AD Phase 2 trial. Positive signal in the DLB AscenD-LB trial, though subsequent replication failed (formulation issue acknowledged).

Promising potential: 3/5. Active development continues in DLB and FTD, with the AD indication deprioritized but not formally abandoned. The p38 MAPK mechanism retains pharmacological plausibility.

Side-effect profile: 5/5. Excellent tolerability across all completed trials. No drug-related serious adverse events and no withdrawals due to adverse effects in AscenD-LB [38].

Overall validation: 2/5. The compound has produced mixed results across multiple indications. The single positive Phase 2 trial in DLB was not replicated, though a formulation issue was identified. Validation of the p38 MAPK mechanism in neurodegeneration remains incomplete.

Comparison to simufilam: Both compounds are oral small molecules targeting non-amyloid, non-cholinergic mechanisms in neurodegeneration. Both failed their respective AD Phase 2 trials. Neflamapimod's development is ongoing with a pivot to DLB; simufilam's development is discontinued entirely. Neflamapimod's mechanism is independently validated by multiple research groups (p38 MAPK is a well-characterized target); simufilam's mechanism lacks independent replication. Both compounds demonstrate excellent tolerability.

12.6 Comparator summary

STANDARD	SIMUFILAM	LECANEMAB	DONANEMAB	GV-971	AZELIRAGON	NEFLAMAPIMOD
Novelty	4	3	3	4	3	4
Effect size	1	3	4	3	1	2
Promising potential	1	5	5	2	1	3
Side-effect profile	4	2	2	4	3	5
Overall validation	1	5	5	2	2	2

Simufilam's position in this comparator landscape is defined by two attributes: a novel but unvalidated mechanism and a complete Phase 3 clinical failure accompanied by data integrity concerns. The compound's proposed FLNA conformation-modulation mechanism, if it could be independently validated, would represent a genuinely first-in-class therapeutic concept. However, the absence of independent replication, the Phase 3 failure on all endpoints including biomarkers, the negative independent cell-culture assessment, and the extensive data integrity controversies collectively place simufilam at the bottom of the validation hierarchy among the comparators evaluated. The approved anti-amyloid antibodies (lecanemab, donanemab) have demonstrated replicated clinical efficacy with independently validated mechanisms, though at the cost of meaningful ARIA risk and the requirement for intravenous infusion and MRI monitoring. GV-971 and neflamapimod occupy intermediate positions with single-trial signals and ongoing questions. Azeliragon's trajectory most closely parallels simufilam's: a novel oral mechanism that failed Phase 3, though without the accompanying data integrity issues.

Investigators considering the FLNA-Aβ42-α7nAChR signaling axis as a research target should note that the mechanistic hypothesis itself (that altered FLNA enables pathogenic Aβ42 signaling) has not been independently confirmed, and the only clinical test of this hypothesis (simufilam Phase 3) produced null results. Whether this reflects a true-negative test of an invalid hypothesis, or whether confounding factors (e.g., the 20.6 percent amyloid-negative enrollment in ReFocus-ALZ, the unresolved questions about Phase 2 data accuracy) prevent a clean interpretation of the Phase 3 outcome is an open scientific question.

13. References

1. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Bhatt DP, Burns LH. Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. *J Neurosci*. 2012;32(29):9773-9784. PMID: 22815492. PMCID: PMC6621293. [Expression of concern published December 2021]
2. Wang HY, Lee DH, Davis CB, Bhatt DP, Burns LH. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis. *Neurobiol Aging*. 2017;55:99-114. PMID: 28438486.
3. Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Burns LH. Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer's disease. *Neuroimmunol Neuroinflammation*. 2017;4(12):263-271. PMID: 34295950. PMCID: PMC8294116.
4. Wang HY, Pei Z, Lee KC, et al. Simuflam reverses aberrant receptor interactions of filamin A in Alzheimer's disease. *Int J Mol Sci*. 2023;24(18):13927. PMCID: PMC10531384.
5. Wang HY, Pei Z, Lee KC, et al. Simuflam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer's disease patient lymphocytes. *Front Aging*. 2023;4:1175601. PMCID: PMC10339288.
6. Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Burns LH. PTI-125 reduces biomarkers of Alzheimer's disease in patients. *J Prev Alzheimers Dis*. 2020;7(4):256-264.
7. Burns LH, Pei Z, Wang HY. Phase 3 randomized clinical trials of simuflam in mild-to-moderate Alzheimer's disease. *J Prev Alzheimers Dis*. 2026;13(3):100469. PMCID: PMC12988371. DOI: 10.1016/j.tjpad.2025.100469.
8. Srivastava S, et al. Simuflam in Alzheimer's disease: assessment of efficacy of a controversial drug in human neuronal cell culture. *Pharmaceuticals (Basel)*. 2026;19(2):281. PMCID: PMC12944517.
9. Fluegge K, Fluegge K. Comment on Wang et al. Simuflam reverses aberrant receptor interactions of filamin A in Alzheimer's disease. *Int. J. Mol. Sci*. 2023, 24, 13927. *Int J Mol Sci*. 2025;26(6):2480. PMCID: PMC11942311.

10. PubChem. Simufilam. CID 46195331. National Library of Medicine, National Center for Biotechnology Information. Accessed May 22, 2026.
11. DrugBank Online. Simufilam (DB18817). Accessed May 22, 2026.
12. ClinicalTrials.gov. A safety study of PTI-125 in healthy volunteers. NCT03784300. U.S. National Library of Medicine.
13. ClinicalTrials.gov. PTI-125 for mild-to-moderate Alzheimer's disease patients. NCT03748706. U.S. National Library of Medicine.
14. ClinicalTrials.gov. Open-label extension of the PTI-125-04 study in mild-to-moderate Alzheimer's disease. NCT04079803. U.S. National Library of Medicine.
15. ClinicalTrials.gov. Simufilam (PTI-125), 100 mg, for mild-to-moderate Alzheimer's disease patients. NCT04388254. U.S. National Library of Medicine.
16. ClinicalTrials.gov. Food effect and bioequivalence study of simufilam tablets in healthy volunteers. NCT04932655. U.S. National Library of Medicine.
17. ClinicalTrials.gov. Simufilam 100 mg for mild-to-moderate Alzheimer's disease (ReThink-ALZ). NCT04994483. U.S. National Library of Medicine.
18. ClinicalTrials.gov. Simufilam 50 mg or 100 mg for mild-to-moderate Alzheimer's disease (ReFocus-ALZ). NCT05026177. U.S. National Library of Medicine.
19. ClinicalTrials.gov. Open-label extension for Phase 3 clinical trials of simufilam. NCT05575076. U.S. National Library of Medicine.
20. ALZFORUM. Simufilam therapeutics page.
<https://www.alzforum.org/therapeutics/simufilam>. Accessed May 22, 2026.
21. Piller C. Co-developer of Cassava's potential Alzheimer's drug cited for 'egregious misconduct.' Science. October 2023. DOI: 10.1126/science.adl2998.
22. Piller C. U.S. levels fraud indictment at CUNY scientist who helped Alzheimer's drug developer. Science. July 2024.
23. Piller C. Controversial Alzheimer's drug from Cassava Sciences fails clinical testing. Science. November 2024.

24. Piller C. 'Damning' FDA inspection report undermines positive trial results of possible Alzheimer's drug. Science. 2024.
25. Piller C. Company misled investors on possible Alzheimer's drug, SEC charges. Science. September 2024.
26. Piller C. Justice Department unexpectedly drops fraud case against Alzheimer's scientist. Science. October 2025.
27. Piller C. As his fraud trial looms, Alzheimer's scientist is exonerated by his university, sort of. Science. May 2024.
28. Retraction Watch. 'Rare' criminal charges for data manipulation in Cassava case send a 'powerful message': lawyers. July 11, 2024.
29. Retraction Watch. Two expressions of concern arrive for papers linked to beleaguered biotech Cassava. December 20, 2021.
30. STAT News. FDA rejects petition to halt trials of Cassava Sciences Alzheimer's drug. February 11, 2022.
31. Cassava Sciences, Inc. SEC Form 8-K filing. Announcement of ReThink-ALZ topline results and discontinuation of ReFocus-ALZ. November 25, 2024.
32. U.S. Securities and Exchange Commission. SEC charges Cassava Sciences and former executives with securities fraud relating to Alzheimer's drug. Press release. September 26, 2024.
33. Retraction note: Increased Abeta42-alpha7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer's disease pathogenesis. Alzheimers Dement. 2022. PMID: 35650632.
34. Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia. Alzheimers Res Ther. 2021;13(1):62. PMID: 33731209.
35. ALZFORUM. GV-971 therapeutics page.
<https://www.alzforum.org/therapeutics/gv-971>. Accessed May 22, 2026.
36. Burstein AH, Grimes I, Galasko DR, Aisen PS, Bhatt DP, Burns LH. Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer's disease. J Prev Alzheimers Dis. 2018;5(3):149-154. PMID: 29616709.

37. ALZFORUM. Azeliragon therapeutics page.
<https://www.alzforum.org/therapeutics/azeliragon>. Accessed May 22, 2026.
38. ALZFORUM. Neflamapimod therapeutics page.
<https://www.alzforum.org/therapeutics/neflamapimod>. Accessed May 22, 2026.
39. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21.
40. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA*. 2023;330(6):512-527.
41. Piller C. Research backing experimental Alzheimer's drug was first target of suspicion. *Science*. 2022. DOI: 10.1126/science.ade0181.
42. STAT News. In new remarks, Cassava Sciences' CEO shifts defense of embattled treatment for Alzheimer's. September 13, 2021.
43. Alzheimer's Drug Discovery Foundation. Simuflam (PTI-125) Cognitive Vitality Report. Accessed May 22, 2026.
44. Being Patient. Cassava rebukes fraud allegations, faces calls to halt Alzheimer's drug Phase III trials. 2021.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Simuflam is not approved by the United States Food and Drug Administration or any other regulatory authority for any indication. The compound's proposed molecular mechanism has not been independently replicated by laboratories outside the sponsoring research group, and the foundational preclinical publications have been the subject of data integrity investigations, expressions of concern, and retractions. Two large Phase 3 randomized controlled trials found no cognitive or functional benefit over placebo. Investigators considering research applications involving simuflam should weigh these factors in their experimental design and interpretation of results.